Factors such as growing awareness about various health-related disorders among women, rising incidence of various chronic and lifestyle disorders in women, and high prevalence of infectious diseases such as HIV and hepatitis in women across the globe are driving the growth of the market. Moreover, the increasing adoption of point-of-care diagnostic testing and the increasing number of diagnostic and imaging centers are also expected to play a major role in market growth.
The global women’s health diagnostics market is projected to reach USD 36.64 Billion by 2021 from USD 25.03 Billion in 2016, at a CAGR of around 7.9% during the forecast period. Women’s Health Diagnostics Market by Application (Prenatal Testing, Down Syndrome, HPV, Fertility Test, Pregnancy Test, Urinary Tract Infections, Osteoporosis, Breast, Cervical and Ovarian Cancer Test) End User (Hospitals, Home Care) – Forecast to 2021.
Global women health diagnostics market is segmented on the basis of application and end user. On the basis of application, the market is segmented into nine segments namely, osteoporosis testing, ovarian cancer testing, cervical cancer testing, breast cancer testing, pregnancy & ovulation testing, prenatal genetic screening & carrier testing, infectious disease testing, sexually transmitted disease testing, and ultrasound.
The osteoporosis segment is further divided into bone densitometry and in vitro blood tests. The ovarian cancer segment is divided into tumor marker tests, diagnostic imaging tests and others. The cervical cancer segment is sub segmented into PAP smear testing and HPV testing. The breast cancer testing segment is further divided into mammography, tumor marker tests, blood cell count & blood chemistries, biopsies and other diagnostic imaging tests.
Download PDF Brochure: www.marketsandmarkets.com/pdfdownloadNew.asp?id=128928901
The prenatal genetic screening & carrier testing segment is further divided into cystic fibrosis, Down syndrome and Edward syndrome, TORCH infections and others (fragile x-syndrome & tay-sachs diseases). Further on, the infectious disease testing market segment is sub segmented into methicillin-resistant staphylococcus aurea (MRSA), urinary tract infections (vaginal pH & vaginitis), hepatitis, tuberculosis, and others infectious disease testing.
The sexually transmitted disease testing segment comprises Chlamydia Trachomatis and Neisseria Gonorrohoeae testing, HIV testing and other STD testing.. The ultrasound segment covers breast imaging and ob/gyn imaging. On the basis of end user, the market is segmented into hospitals & clinics, home care, and diagnostic & imaging centers.
Region Covered in Women’s Health Diagnostics Market :
Geographically, the global market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. In 2015, North America commanded the largest share of the global women health diagnostics market. The major share of this region can be attributed to increasing prevalence of cancer among women in this region, increasing incidence of lifestyle related health disorders, growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and increasing demand for fertility testing monitors.
Request for Sample Pages: www.marketsandmarkets.com/requestsampleNew.asp?id=128928901
Key Players in Women’s Health Diagnostics Market :
The prominent players in this market are Siemens AG (Germany), Quest Diagnostics Inc. (U.S.), Hologic, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), PerkinElmer Inc. (U.S.), Alere Inc. (U.S.), GE Healthcare (U.S.), Becton, Dickinson and Company (BD) (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), and Koninklijke Philips N.V. (Netherlands).